PCSK9与尿血栓素排泄对房颤患者心血管事件的关系
该前瞻性单中心队列研究纳入907例接受维生素K拮抗剂治疗的房颤患者,随访3865患者年,旨在评估血浆PCSK9水平与心血管事件的关系及其与尿11-脱氢血栓素B2的相关性。结果显示PCSK9第三分位组心血管事件风险显著高于第一分位组,且PCSK9与11-dh-TxB2显著相关,提示PCSK9可能参与血小板活化机制。
要点
- 房颤患者血浆PCSK9水平升高与心血管事件风险增加独立相关。
- PCSK9与尿11-dh-TxB2显著相关,提示其可能参与血小板活化。
- 该关联在未接受抗血小板治疗的患者中尤为明显。
核心结论
- 血浆PCSK9水平与房颤患者心血管事件风险增加相关。
- PCSK9与11-dh-TxB2的直接相关提示PCSK9可能是血小板活化的潜在机制。
研究设计与样本
- 前瞻性、单中心队列研究,纳入907例接受维生素K拮抗剂治疗的房颤患者,共3865患者年。
- 入院时测量血浆PCSK9和尿11-dh-TxB2(n=852),按PCSK9三分位分组分析。
主要发现
- 随访期间共发生179例心血管事件(4.6%/年),PCSK9第一、第二、第三分位组分别发生43例(15.3%)、49例(15.5%)和87例(28.0%)(log-rank检验p=0.009)。
- 发生心血管事件的患者PCSK9中位数高于未发生者(1500 pg/ml [IQR: 1000-2300 pg/ml] vs. 1200 pg/ml [IQR: 827-1807 pg/ml],p<0.001)。
- 多变量Cox回归显示,PCSK9第三分位相对于第一分位的心血管事件风险比为1.640(95%CI: 1.117-2.407,p=0.012)。
- 在682例未接受抗血小板治疗的患者中,循环PCSK9与11-dh-TxB2显著相关(Spearman's rho=0.665,p<0.001)。
临床怎么用
- 对于房颤患者,检测血浆PCSK9水平可能有助于识别心血管事件高风险个体。
- PCSK9与血小板活化的关联提示未来可探索针对PCSK9的干预对房颤患者血栓风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Soluble proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular events (CVEs) in patients who are at high cardiovascular risk. No data on the effect of PCSK9 levels in patients with atrial fibrillation (AF) are available. OBJECTIVES: This study investigated the association between PCSK9 and CVEs in AF as well as the relationship between PCSK9 and urinary 11-dehydro-thromboxane B2 (11-dh-TxB2), a marker of platelet activation. METHODS: We conducted a prospective, single-center cohort study, including 907 patients with AF treated with vitamin K antagonists (3,865 patient-years), to assess CVEs, including fatal and nonfatal myocardial infarction, ischemic stroke, and cardiovascular death. At admission, plasma PCSK9 and urinary 11-dh-TxB2 (n = 852) were measured. The population was divided into tertiles of PCSK9 for the analysis. RESULTS: The mean age of patients was 73.5 ± 8.2 years, and 43.0% were women. At follow-up, 179 CVEs (4.6%/year) occurred: 43 (15.3%), 49 (15.5%), and 87 (28.0%) in the first, second, and third tertiles of PCSK9, respectively (log-rank test p = 0.009). Patients with CVEs had higher median PCSK9 compared with those without (1,500 pg/ml [IQR: 1,000 to 2,300 pg/ml] vs. 1,200 pg/ml [IQR: 827 to 1,807 pg/ml], respectively; p < 0.001). Multivariable Cox regression analysis showed that the third versus the first tertile of PCSK9 (hazard ratio: 1.640; 95% confidence interval: 1.117 to 2.407; p = 0.012), female sex, age, diabetes, smoking, heart failure, previous cerebrovascular and cardiac events, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associated with CVEs. In 682 patients not treated with antiplatelet therapy, circulating PCSK9 and 11-dh-TxB2 were significantly correlated (Spearman's rho: 0.665; p < 0.001). CONCLUSIONS: Plasma PCSK9 levels are associated with an increased risk of CVEs in patients with AF. The direct correlation between PCSK9 and 11-dh-TxB2 suggests PCSK9 as a mechanism potentially implicated in platelet activation.
引用
- Pastori D, Nocella C, Farcomeni A, et al. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017. PMID: 28911508. doi:10.1016/j.jacc.2017.07.743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。